Interleukin-6 Induces Oxidative Stress and Endothehal Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor

Circulation Research

Volumn 94, Issue 4, 2004, Pages 534-541

  Wassmann, Sven ^a   Stumpf, Michaela ^a   Strehlow, Kerstin ^a   Schmid, Andreas ^a   Schieffer, Bernhard ^b   Böhm, Michael ^a   Nickenig, Georg ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

AT1 receptor; Endothelial dysfunction; Inflammation; Interleukin 6; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FLUORESCENCE; INFLAMMATION; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; WESTERN BLOTTING;

ANIMALS; AORTIC DISEASES; ARTERIOSCLEROSIS; CROSSES, GENETIC; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECOMBINANT PROTEINS; RENIN-ANGIOTENSIN SYSTEM;

EID: 1542313876     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000115557.25127.8D     Document Type: Article

References (43)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-1266.
4. Vita JA, Keaney JF. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106:640-642.
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000:101:948-954.
6. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
7. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
8. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y, Kano S. Interleukin-6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260:H1713-H1717.
9. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;294:894-897.
10. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
11. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
12. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part II: AT1 receptor regulation. Circulation. 2002;105:530-536.
13. Han Y, Runge MS, Brasier AR. Angiotensin II induces IL-6 transcription in vascular smooth muscle cells through pleiotropic activation of NF-κB transcription factors. Circ Res. 1999;84:695-703.
14. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-1378.
15. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195-1201.
16. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999;34:118-125.
17. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
18. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A. 1995;92:3521-3525.
19. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75-79.
20. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450-1457.
21. Sohn HY, Gloe T, Keller M, Schoenafinger K, Pohl U. Sensitive superoxide detection in vascular cells by the new chemiluminescence dye L-012. J Vasc Res. 1999;36:456-464.
22. Hensold JO, Barth D, Stratton CA. RNA polymerase II inhibitor, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), causes erythroleukemic differentiation and transcriptional activation of erythroid genes. J Cell Physiol. 1996;168:105-113.
23. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
24. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
25. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction: modulation by statins. Endothelium. 2003;10:23-33.
26. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction mice. Circ Res. 2002;91:173-179.
27. Nickenig G, Röling J, Strehlow K, Schnabel P, Böhm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453-2460.
28. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and posttranscriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995;48:601-609.
29. Nickenig G, Bäumer AT, Grohé C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JFM, Daemen MJAP, Vetter H, Böhm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197-2201.
30. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
31. Nickenig G, Strehlow K, Wassmann S, Bäumer AT, Ahlbory K, Sauer H, Böhm M. Differential effects of estrogen and progesterone on AT1 receptor gene expression in vascular smooth muscle cells. Circulation. 2000;102:1828-1833.
32. Nickenig G, Murphy TJ. Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression. Mol Pharmacol. 1994;46:653-659.
33. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-2367.
34. Strawn WB, Chapell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
35. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. Circulation. 1996;94:258-265.
36. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, Ellahham S, Quyyumi AA. Acute and chronic angioten-sin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
37. Schiffrin EL, Park JB, Intengan HD, Touyz R. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-1659.
38. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
39. Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events. N Engl J Med. 2000;342:145-153.
40. Consensus Trial Study Group. Effects of enalapriI on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med. 1987;316:1429-1435.
41. Ohkawa F, Ikeda U, Kanbe T, Kawasaki K, Shimada K. Effects of inflammatory cytokines on vascular tone. Cardiovasc Res. 1995;30:711-715.
42. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370-2376.
43. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.